hydroxychloroquine + clindamycin + primaquine

This is a combination of three drugs—hydroxychloroquine, clindamycin, and primaquine—each with distinct mechanisms of action. Hydroxychloroquine is an antimalarial and immunomodulatory agent used for malaria treatment and prophylaxis as well as autoimmune diseases. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis, used to treat various bacterial infections and sometimes in combination regimens for malaria or Pneumocystis pneumonia. Primaquine is an 8-aminoquinoline antimalarial effective against liver-stage hypnozoites of Plasmodium vivax and Plasmodium ovale, also used in combination with other agents for Pneumocystis jirovecii pneumonia (PCP). The triple combination may be considered in complex or resistant infections where multiple pathogens or life cycle stages are targeted; however, the most common clinical combinations are clindamycin plus primaquine (for PCP) or hydroxychloroquine plus primaquine (for malaria relapse prevention), not all three together[1][2][3][4][5].